Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET

Journal of Nuclear Medicine

Volumn 52, Issue 10, 2011, Pages 1608-1615

  Ruggiero, Alessandro ^a   Holland, Jason P ^a   Hudolin, Tvrtko ^a   Shenker, Larissa ^a   Koulova, Anna ^a   Bander, Neil H ^a,b   Lewis, Jason S ^a   Grimm, Jan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

7E11; 89Zr; Monoclonal antibodies; PET; Prostate cancer; PSMA

Indexed keywords

7 AMINODACTINOMYCIN; CAPROMAB PENDETIDE IN 111; CASPASE 3; EPITOPE; ETOPOSIDE; FLUTAMIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL DEATH; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE DISPLAY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE DAMAGE; MICROSCOPY; MOUSE; NONHUMAN; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; AUTORADIOGRAPHY; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; EPITOPES; HUMANS; MALE; MICE; MICE, SCID; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; ZIRCONIUM;

EID: 80053527523     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.092098     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Attard G, De Bono JS. Prostate cancer: PSA as an intermediate end point in clinical trials. Nat Rev Urol. 2009;6:473-475.
3. 11C-choline. J Nucl Med. 2011;52:81-89.
4. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organconfined prostate cancer. Urology. 2001;57:108-111. (Pubitemid 32065829)
5. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22:963-969. (Pubitemid 32783446)
6. Haberkorn U, Bellemann ME, Altmann A, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med. 1997;38:1215-1221. (Pubitemid 27332617)
7. 18F- fluorodeoxyglucose PET. Nat Rev Urol. 2009;6:317-323.
8. Jadvar H. Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. 2009;8:56-64.
9. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334. (Pubitemid 26279634)
10. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167-172.
11. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927-935. (Pubitemid 18036141)
12. Bander NH. Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol. 2006;3:216-225.
13. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: positron emission tomography and biopsy correlation. Clin Nucl Med. 1996;21:704-713. (Pubitemid 26303725)
14. Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. J Urol. 1994;152:1952-1955. (Pubitemid 24354699)
15. Polascik TJ, Manyak MJ, Haseman MK, et al. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer. 1999;85:1586-1592. (Pubitemid 29152832)
16. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031-2041.
17. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med. 2003;44:610-617. (Pubitemid 40003748)
18. 89Zr- DFO-J591 for immunoPET imaging of prostate-specific membrane antigen (PSMA) expression in vivo. J Nucl Med. 2010;51:1293-1300.
19. 89Zr- DFO-trastuzumab. PLoS ONE. 2010;5:e8859.
20. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629-3634. (Pubitemid 27381196)
21. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055-4060. (Pubitemid 28440554)
22. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostatespecific membrane antigen. Neoplasia. 1999;1:123-127.
23. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
24. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36:729-739.
25. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193-207. (Pubitemid 351499295)
26. Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging. 2010;9:1-20.
27. 177Lu-7E11 radioimmunotherapy. Mol Imaging Biol. 2009;11:159-166.
28. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237-5243.
29. De Saint-Hubert M, Prinsen K, Mortelmans L, Verbruggen A, Mottaghy FM. Molecular imaging of cell death. Methods. 2009;48:178-187.
30. Mandl SJ, Mari C, Edinger M, et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging. 2004;3:1-8.
31. Khaw BA. The current role of infarct avid imaging. Semin Nucl Med. 1999; 29:259-270.
32. 99mTc-glucarate be used to evaluate tumour necrosis? In vitro and in vivo studies in leukaemic tumour cell line U937. Eur J Nucl Med Mol Imaging. 2008;35:1290-1298.
33. Khaw BA, Fallon JT, Beller GA, Haber E. Specificity of localization of myosinspecific antibody fragments in experimental myocardial infarction. Histologic, histochemical, autoradiographic and scintigraphic studies. Circulation. 1979; 60:1527-1531. (Pubitemid 10207883)